SI-BONE Recalls 98 iFuse TORQ Implants Over Sterility Risk; Two Already Implanted
SIBN sits 69% above its 52-week low of $11.48.
Summary
SI-BONE voluntarily recalled 98 iFuse TORQ implants due to a packaging sterility failure; two were already implanted with no reported adverse events. Expected charges are up to $150,000, and the company also extended its HQ lease by one month.
Key Events · Product Development and Regulatory · SIBN
-
Voluntary Recall of 98 iFuse TORQ Implants
A recall of 98 iFuse TORQ implants from specific lots was initiated because tube packaging failed sterility acceptance criteria, posing an infection risk.
-
Two Implants Already in Patients
Two recalled implants had already been implanted; the physicians were notified, and no infections or adverse events have been reported to date.
-
FDA Report Submitted; Class II Recommended
A report of correction and removal was submitted to the FDA on August 31, 2026, and a Class II recall classification was recommended based on the company's health hazard evaluation.
-
Financial Impact Up to $150,000
An aggregate gross charge of up to approximately $150,000 is expected in Q3 and Q4 cost of goods sold for recall, repackaging, and re-sterilization activities, with possible recovery from the tube manufacturer.
Analysis · SIBN · Industrial Applications And Services
A voluntary recall of 98 iFuse TORQ implants was disclosed after tube packaging failed sterility acceptance criteria. Two of the recalled implants had already been implanted in patients, though no infections or adverse events have been reported. The company expects up to $150,000 in charges across Q3 and Q4 and is seeking recovery from the tube manufacturer. While the financial impact is modest, the recall involves a flagship product and patient-safety risk, and the FDA classification is still pending — a Class II recall is recommended but not yet confirmed. Separately, the company extended its headquarters lease by one month at $43,696 per month, a routine administrative step.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 30.2% of the 1943 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.21%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SIBN was trading at $19.39 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $823.8M. The 52-week trading range was $11.48 to $21.89. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.